Acquisitions (Allocation Of The Preliminary Purchase Price To The Acquired Net Assets Of The Surpass, Neurovascular, Orthovita, Memometal and Concentric Acquisitions) (Details) (USD $) In Millions, unless otherwise specified	Dec. 31, 2013 MAKO [Member]	Dec. 31, 2013 MAKO [Member] Customer relationship	Dec. 31, 2013 MAKO [Member] Trade Names [Member]	Dec. 31, 2013 MAKO [Member] Developed technology	Dec. 31, 2013 MAKO [Member] In-process research & development	Dec. 31, 2013 Trauson [Member]	Mar. 31, 2013 Trauson [Member]	Dec. 31, 2013 Trauson [Member] Customer relationship	Dec. 31, 2013 Trauson [Member] Trade Names [Member]	Dec. 31, 2013 Trauson [Member] Developed technology	Dec. 31, 2013 Trauson [Member] In-process research & development	Dec. 31, 2012 Surpass	Nov. 30, 2012 Surpass	Dec. 31, 2012 Surpass Customer relationship	Dec. 31, 2012 Surpass Trade Names [Member]	Dec. 31, 2012 Surpass Developed technology	Dec. 31, 2012 Surpass In-process research & development
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Debt	$ 1,679					$ 751	$ 751					$ 133	$ 100
Business Acquisition, Cost of Acquired Entity, Cash Paid Excluding Contingent Consideration												100
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low	0					0						33	35
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	50					43						2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Other	174					163						1
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(277)					(87)						(28)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		91	24	231	169			112	34	31	5			0	0	45	19
Business Acquisition, Goodwill, Expected Tax Deductible Amount	$ 1,217					$ 450						$ 94